Memantina Tolife (Memantine Hydrochloride)

Memantine blocks the NMDA‑type glutamate receptors in a non‑competitive manner. By limiting excessive calcium entry caused by glutamate over‑activation, it reduces excitotoxic neuronal damage that contributes to cognitive decline in Alzheimer’s disease.

The exact dose of Memantina Tolife is determined by the prescribing clinician based on the patient’s clinical condition, renal function, and tolerability. Dosage adjustments are made individually and should follow the prescriber’s instructions.

Safety data for memantine in pregnancy and lactation are limited. The product’s pregnancy category is unknown, so it should only be used when the potential benefit justifies any possible risk to the fetus or infant. Consultation with a healthcare professional is essential.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Memantine belongs to the NMDA receptor antagonist class, whereas other approved agents such as cholinesterase inhibitors (donepezil, rivastigmine) act on the cholinergic system. Memantine is typically used in moderate to severe stages and may be combined with a cholinesterase inhibitor for additive benefit.

Memantina Tolife should be stored below 25 °C in its original packaging, protected from moisture and direct sunlight. Do not store in humid environments or near heat sources to maintain product stability.

The medication is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious adverse events, although rare, include seizures, hallucinations or psychosis, severe skin reactions, significant liver enzyme elevations, suicidal thoughts, and cardiac arrhythmias. Patients should be monitored closely for any of these symptoms and seek immediate medical attention if they occur.

Memantina Tolife is contraindicated in patients with known hypersensitivity to memantine or any excipients in the formulation. Caution is advised for individuals with severe renal impairment, uncontrolled hypertension, or a history of seizures, and it should be avoided in those where the risk outweighs potential benefit.